The Ministry of Health is asking the healthcare sector to promote careful use of weight and metabolic drugs, warning that misuse could carry risks.
Recap by typeshit. Post by @informante_news on Instagram.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Box Life Magazine says new Oxford research paints a sobering picture of GLP-1 weight loss drugs like Ozempic and Wegovy, but its post gives no findings and is gated behind comment bait.
The forecast puts 2025 sales at $45.8 billion, with Zepbound's $22.9 billion edging past Wegovy's $18.6 billion last year.
Loading…